Bradley McGregor, MD, discusses the current treatment landscape for patients with advanced or metastatic renal cell carcinoma, which has significantly evolved over the last few years.
Brad McGregor, MD
Advertisement
Articles by Brad McGregor, MD
Brad McGregor, MD, a medical oncologist at Dana-Farber Cancer Institute, discusses the future of combination therapies in the treatment landscape of renal cell carcinoma. He highlights the positive results from a few combinations that have been tested in clinical trials.
Advertisement
Latest Updated Articles
Combination Therapies Emerge in the Frontline for Renal Cell CarcinomaPublished: April 30th 2018 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5
